Cosmetic and Regenerative Medicine, Sun Field Clinic, Koto-ku, Tokyo, Japan.
Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1570-1578. doi: 10.26355/eurrev_202203_28223.
Several studies in animal models have shown the safety and effectiveness of mesenchymal stem cell conditioned medium (MSC-CM) in inflammatory lesions involving muscles and joints.
In this report, we retrospectively evaluated 16 patients who received local administration of the human adipose-derived mesenchymal stem cells conditioned medium (hAMSC-CM) for musculoskeletal chronic pain. Overall, 27 body locations expressing pain have been treated. The local administrated dose was 5 ml in the joint cavity and/or 2 ml in the other locations. The patients were asked to conduct self-evaluation of the degree of pain using a numeric rating scale (NRS) questionnaire and record the severity of pain before administration and at 15 min, 1 day, 1 week, and 4 weeks after administration. A second administration has been performed in 7 locations. The analysis was done considering two conditions: the "current pain status" and the "worst pain status in a week."
The results showed statistically significant differences between before and after administration at each time point for "current pain status" and at 1-week and 4-week time points for "worst pain status in a week" after first administration (Tukey-Kramer test). After second administration, significant differences were found at 1-week and 4-week time points for "current pain status". No serious adverse effect was found.
It was concluded that local administration of hAMSC-CM appears to be safe and could be expected to have effective therapeutic value against musculoskeletal chronic pain. Further studies are needed to clarify analgesic effects of hAMSC-CM and its underlying mechanism(s).
几项动物模型研究表明，间充质干细胞条件培养基（MSC-CM）在涉及肌肉和关节的炎症病变中是安全有效的。
在本报告中，我们回顾性评估了 16 名接受局部注射人脂肪间充质干细胞条件培养基（hAMSC-CM）治疗肌肉骨骼慢性疼痛的患者。总共治疗了 27 个表达疼痛的身体部位。关节腔内局部注射剂量为 5ml，其他部位为 2ml。患者使用数字评分量表（NRS）问卷自行评估疼痛程度，并记录给药前和给药后 15 分钟、1 天、1 周和 4 周时的疼痛严重程度。有 7 个部位进行了第二次给药。分析考虑了两种情况：“当前疼痛状况”和“一周内最严重的疼痛状况”。
首次给药后，“当前疼痛状况”在每个时间点，以及“一周内最严重的疼痛状况”在 1 周和 4 周时间点，结果均显示统计学差异（Tukey-Kramer 检验）。第二次给药后，“当前疼痛状况”在 1 周和 4 周时间点均有显著差异。未发现严重不良事件。
局部注射 hAMSC-CM 似乎是安全的，并可能对肌肉骨骼慢性疼痛具有有效的治疗价值。需要进一步研究以阐明 hAMSC-CM 的镇痛作用及其潜在机制。
